Latigo Biotherapeutics (LTGO) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 17 65 sessions, August 7, 2026 to November 6, 2026
- Largest daily move
- -11.1% close of September 24, 2026
- 1-month change
- -22.5% closing prices, October 6, 2026 to November 6, 2026
Company Description
Latigo Biotherapeutics (NASDAQ: LTGO) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $815.5M.
LTGO has declined 22.5% over the past month. The last closing price was $12.60.
This page collects what Stock Titan holds for LTGO, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Latigo Biotherapeutics (LTGO) closed at $12.60 on November 6, 2026. Over the past month, the price has lost 22.5%.
LTGO Metrics & Rankings
Price returns through November 6, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Latigo Biotherapeutics has 5 recent news articles, with the latest published 2 days ago. Of the recent coverage, 1 article coincided with positive price movement and 3 with negative movement. Key topics include earnings, conferences, IPO, offering. View all LTGO news →
SEC Filings
Latigo Biotherapeutics has filed 10 recent SEC filings, including 4 Form SCHEDULE 13G, 2 Form 10-Q, 2 Form 8-K, 1 Form SCHEDULE 13G/A. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LTGO SEC filings →
Insider Radar
Insider buying activity at Latigo Biotherapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Upcoming Events
Guggenheim fireside chat
Jefferies fireside chat
Advisor term end
Onzotrigine topline results
LTG-321 topline results
Phase 3 topline data
Latigo Biotherapeutics has 6 upcoming scheduled events. The next event, "Guggenheim fireside chat", is scheduled for November 10, 2026 (in 3 days). Investors can track these dates to stay informed about potential catalysts that may affect the LTGO stock price.
Short Interest History
Short interest in Latigo Biotherapeutics (LTGO) currently stands at 785.9 thousand shares, down 5.5% from the previous reporting period, representing 1.5% of the float. Since August 2026, short interest has increased by 484.4%.
Days to Cover History
Days to cover for Latigo Biotherapeutics (LTGO) currently stands at 2.5 days, up 56.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since August 2026, the figure has increased by 150%. Across the settlements charted above, it has ranged from 1.0 to 2.5 days.
LTGO Company Profile & Sector Positioning
Latigo Biotherapeutics (LTGO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing LTGO often look at related companies in the same sector, including Pharming Group N.V. (PHAR), MeiraGTx Holdings plc (MGTX), Syndax Pharmaceuticals, Inc. (SNDX), Obsidian Therapeutics, Inc. (OBX), and Prime Medicine, Inc. (PRME). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate LTGO's relative position within its industry.